Market Overview

UPDATE: Bank of America Merrill Lynch Downgrades Merck to Neutral, Reiterates $45 PT

Related MRK
US FDA Accepts For Review A Biologics License Application For Merck And Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine
Will Actavis Win Competition For Allergan's Affection?
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

In a report published Friday, Bank of America Merrill Lynch downgraded its rating on Merck & Co. (NYSE: MRK) to Neutral, and reiterated its $45.00 price target.

BofA Merrill Lynch noted, “With MRK shares up 14% this year, and with only modest upside potential to our $45 price objective, we are moving to Neutral. As we have been since our March 2011 launch, we remain more bullish than our peers on Major Pharma with 3 Buys and 1 Neutral...Our move to Neutral on MRK is not at all a ‘sell' call, as we remain constructive on management's strategy and track record of returning cash to shareholders...MRK recently stopped the odanacatib (novel oral treatment for osteoporosis) fracture outcomes trial early due to strong efficacy. We will likely see the results at a relevant conference in 2013. Anacetrapib, a CETP inhibitor that raises good cholesterol and lowers bad cholesterol, represents a huge but longer-term, riskier prospect.”

Merck & Co. closed on Thursday at $42.80.

Latest Ratings for MRK

DateFirmActionFromTo
Oct 2014JefferiesMaintainsHold
Oct 2014Guggenheim SecuritiesInitiates Coverage onNeutral
Sep 2014JefferiesMaintainsHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Downgrades Analyst Ratings

 

Related Articles (MRK)

Around the Web, We're Loving...

Get Benzinga's Newsletters